c Includes CHD or CHD risk equivalent, 10-y risk >20%. d Includes ≥2 risk factors, 10-y CHD risk 10-20%. e Includes ≥2 risk factors, 10-y CHD risk <10%. f Includes 0-1 risk factors.

Phase 1 results support proceeding to Phase 2 in patients with post-bariatric hypoglycemia (PBH), which is expected to begin in 2H 2025 Phase 1 trial in healthy volunteers showed MBX 1416 was generall ...

In the MAD cohort, MBX 1416 appeared to increase GLP-1 within 60 minutes of a mixed meal tolerance test, suggesting a pharmacodynamic (PD) effect in healthy volunteers that may translate into a ...

Expert Rev Cardiovasc Ther. 2012;10(10):1329-1333.